Clinical Trial Update: Clinical Protocol to Investigate the Efficacy of Recombinant Human Leptin (Metreleptin) in Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) Associated With Lipodystrophy [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating metreleptin for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis associated with lipodystrophy has complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lipodystrophy
• Nonalcoholic Fatty Liver Disease
• Nonalcoholic Steatohepatitis

Drugs mentioned

• Metreleptin (metreleptin)

Snippet

Sponsor: University of Michigan | Conditions: Fatty Liver Disease, Nonalcoholic, Nonalcoholic Steatohepatitis | Phase 2 | Status: COMPLETED | Results posted: 2017-06-14